Clinical trials: Acute Non-Lymphocytic Leukemia
Acute Myeloid Leukemia
Study Investigating NTLA-5001 in Subjects With Acute Myeloid Leukemia
This study will be conducted to evaluate the safety, tolerability, cellular kinetics (CK), activity, and pharmacodynamics (PD) of NTLA-5001 in participants with Acute Myeloid Leukemia (AML).
- Trial name
- NCT05066165
- Testing
- Arm 1: NTLA-5001, Arm 2: NTLA-5001
- Where
- 10 sites in United States, United Kingdom
- Volunteers
- 6 people
- Sponsor
- Intellia Therapeutics
Leukemia, Myeloid Leukemia
Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia
This is an open label, phase 1 study for AML subjects with relapsed or refractory disease or subjects in morphologic remission with MRD+ after first line therapy with venetoclax+HMA.
- Conditions
- Leukemia, Myeloid Leukemia, Monocytic Leukemia
- Trial name
- NCT06429449
- Testing
- Venetoclax, Azacitidine, Mitoxantrone
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Colorado, Denver
Acute Myeloid Leukemia
Venetoclax Add in Combination With Fludarabine, Cyratabine and Idarubicine in Induction for Acute Myelid Leukemia
This study will test the effectiveness and safety of Venetoclax in combination with standard induction regimen for patients with acute leukemia and poor prognosis.
- Trial name
- V-FIRST (NCT03455504)
- Testing
- Venetoclax
- Where
- 22 sites in Italy
- Volunteers
- 124 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Leukemia
STI571 in Treating Patients With Recurrent Leukemia
RATIONALE: Imatinib mesylate may interfere with the growth of cancer cells and may be an effective treatment for leukemia. PURPOSE: Phase I trial to study the effectiveness of imatinib mesylate in treating patients who have…
- Trial name
- NCT00004932
- Testing
- imatinib mesylate
- Where
- 235 sites in United States, Australia and 5 more
- Volunteers
- 31 people
- Sponsor
- Children's Oncology Group
Acute Myeloid Leukemia, T Cell Acute Lymphoblastic Leukemia
XmAb18968 (CD3-CD38) in Relapsed or Refractory Acute Leukemia and T Cell Lymphoblastic Leukemia
This is a phase 1, dose-escalation study (using 3 + 3 dose-limiting toxicity (DLT) criteria) evaluating the safety and tolerability of XmAb18968, as well as establishing a recommended phase II dose (RP2D) in subjects with T cell…
- Conditions
- Acute Myeloid Leukemia, T Cell Acute Lymphoblastic Leukemia, T Cell Lymphoblastic Lymphoma
- Trial name
- NCT05038644
- Testing
- XmAb18968 - Dose level -1, XmAb18968 - Dose level 0 (starting dose), XmAb18968 - Dose level 1
- Where
- 6 sites in United States
- Volunteers
- 22 people
- Sponsor
- Ehab L Atallah
Acute Myeloid Leukemia
Idarubicin at Different Dosages as Induction Therapy for Newly Diagnosed Acute Myeloid Leukaemia
Study Design: Treatment, Randomized, Open Label, Parallel Assignment This study is an open randomized and controlled trial aiming at assessing the efficacy and safety of Idarubicin (IDA) at different doses of 8mg/m2 and 10mg/m2…
- Trial name
- NCT02277847
- Testing
- Idarubicin(8mg/m2) and cytosine arabinoside, Idarubicin(10mg/m2), cytosine arabinoside
- Volunteers
- 400 people
- Sponsor
- Guangdong Provincial People's Hospital
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer
This phase II trial is studying how well umbilical cord blood transplant from a donor works in treating patients with hematological cancer.
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aggressive Non-Hodgkin Lymphoma, Chronic Myelogenous Leukemia
- Trial name
- NCT00723099
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Cyclosporine
- Where
- 6 sites in United States
- Volunteers
- 73 people
- Sponsor
- Fred Hutchinson Cancer Center
Acute Biphenotypic Leukemia, Acute Leukemia
Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer
This phase II trial studies how well flotetuzumab works in treating patients with CD123 positive blood cancer that has come back or does not respond to treatment.
- Conditions
- Acute Biphenotypic Leukemia, Acute Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hairy Cell Leukemia
- Trial name
- NCT03739606
- Testing
- Anti-CD123/CD3 Monoclonal Antibody MGD006
- Sponsor
- City of Hope Medical Center
B-cell Acute Lymphoblastic Leukemia
Dual-Targeted Umbilical Cord Blood CAR-T Cells Against CD19 and CD22 for the Treatment of Relapsed or Refractory Acute B-Cell Lymphoblastic Leukemia
This investigator-initiated, prospective, single-arm, phase I dose-escalation trial aims to evaluate the safety and tolerability of anti-CD19/CD22 dual-target cord blood-derived CAR-T cells in adult patients with…
- Trial name
- NCT07838714
- Testing
- Anti-CD19/CD22 Dual-Target Cord Blood CAR-T Cells, Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Ruijin Hospital
Acute Myeloid Leukemia
Efficacy Study of Dendritic Cell Vaccination in Patients With Acute Myeloid Leukemia in Remission
The primary aim of this innovative immunotherapeutic study is to determine whether the antileukemic effects seen in our previous phase I/II study can be confirmed in a large cohort of patients and whether dendritic cell…
- Trial name
- WIDEA (NCT01686334)
- Testing
- DC vaccine
- Where
- 8 sites in Belgium
- Volunteers
- 130 people
- Sponsor
- Zwi Berneman
Acute Myeloid Leukemia, Myelodysplastic Syndrome
A Clinical Study of 6MW3211 Monotherapy or Combination Therapy for AML or MDS
This study is aimed to evaluate the efficacy, safety, immunogenicity and pharmkinetics, pharmacodynamics of 6MW3211 as monotherapy and in combination with AZA or AZA plus VEN in patients with AML/MDS.
- Trial name
- NCT05448599
- Testing
- 6MW3211 injection with Intravenous Infusion
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
The Rapid Study: Randomized Phase II Study To Expedite Allogeneic Transplant With Immediate Haploidentical Plus Unrelated Cord Donor Search Versus Matched Unrelated Donor Search For AML And High-Risk MDS Patients
The study seeks to compare time from formal search to hematopoietic cell transplantation (HCT) for patients 18 years and older, randomized between haplo-cord search and matched unrelated donor (MUD) search for patients with acute…
- Trial name
- NCT02648932
- Testing
- Haplo-Cord Transplant, Matched Unrelated Donor Transplant
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Chicago
Blood And Marrow Transplantation, Leukemia
Infusion of Allogeneic, 3rd Party CD19-specific T Cells
The goal of this clinical research study is to learn if researchers can successfully and safely give patients who have had a stem cell transplant an infusion of white blood cells (called T-cells) that have been collected from an…
- Conditions
- Blood And Marrow Transplantation, Leukemia, Lymphoma
- Trial name
- NCT02274506
- Testing
- Cyclophosphamide, Fludarabine, T-Cell Infusion
- Sponsor
- M.D. Anderson Cancer Center
Acute Myeloid Leukemia
Immunotherapy With ex Vivo Expanded Haploidentical Natural Killer Cells for Children/Young Adults With AML
The purpose of this study is to estimate the efficacy of immunotherapy with ex vivo expanded haploidentical NK cells for children/young adults with primary high risk or refractory AML and relapsed AML.
- Trial name
- NCT05272293
- Testing
- NK cell infusions
- Where
- Belarus
- Volunteers
- 15 people
- Sponsor
- Belarusian Research Center for Pediatric Oncology, Hematology and Immunology
AML, RUNX1-RUNX1T1 Fusion Protein Expression
Standard-dose vs Intermediate-dose Cytarabine Induction in the Treatment of Acute Myeloid Leukemia With RUNX1-RUNX1T1
Leukemia is one of the common malignant tumors that threaten human health. Although the efficacy of AML treatment has improved significantly in recent years, it remains one of the major diseases threatening human health.
- Trial name
- NCT06744504
- Testing
- cytarabine, daunorubicin, idarubicin
- Where
- China
- Volunteers
- 284 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
MDS and AML Prior to Allogeneic SCT
Assessment of Body, Liver and Labile Plasma Iron and Their Association With Outcome and Immunological Recovery in Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Patients Undergoing Allogeneic Stem Cell Transplantation - ALLIVE (ALLogeneic Iron inVEstigators) Observational Trial
The ALLIVE (ALLogeneic Iron inVEstigators) trial aims at quantifying the extent and dynamic change of LPI occurrence during conditioning and at identifying LPI-predictive peri-transplant parameters.
- Trial name
- ALLIVE (NCT01746147)
- Testing
- No intervention and study treatment
- Where
- 5 sites in Germany
- Volunteers
- 134 people
- Sponsor
- GWT-TUD GmbH
B-cell Acute Lymphoblastic Leukemia
A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia
The researchers are doing this study to find out whether PK-targeted fludarabine is an effective Lymphodepletion (LD) chemotherapy approach for people with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) who will…
- Trial name
- NCT07223021
- Testing
- Fludarabine, Cyclophosphamide, CAR-T
- Where
- 8 sites in United States, Germany and 1 more
- Volunteers
- 130 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Acute Myeloid Leukemia
First-in-Human Study of FLX925 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia
This first-in-human (FIH) clinical trial is a Phase 1/1b, open-label, sequential-group, dose-escalation and cohort expansion study evaluating the safety, PK, PD, and antitumor activity of FLX925 in subjects with relapsed or…
- Trial name
- NCT02335814
- Testing
- FLX925
- Where
- 12 sites in United States
- Volunteers
- 51 people
- Sponsor
- RAPT Therapeutics, Inc., a member of the GSK plc group of companies
Acute Myeloid Leukemia (AML)
A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy
The primary objective of this study is to evaluate if venetoclax when co administered with low-dose cytarabine (LDAC) improves overall survival (OS) versus LDAC and placebo, in treatment-naïve patients with acute myeloid leukemia…
- Trial name
- NCT03069352
- Testing
- Venetoclax, Cytarabine
- Where
- 109 sites in United States, Argentina and 22 more
- Volunteers
- 211 people
- Sponsor
- AbbVie
Acute Myeloid Leukemia in Remission
Pilot Study of Reduced Venetoclax Exposure
Pilot Study of Reduced Venetoclax Exposure
- Trial name
- NCT07163793
- Testing
- Azacitidine, Decitabine, Venetoclax
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Northwell Health
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.